Monthly Osimertinib Shows Promise in EGFR-Mutated NSCLC

The Food and Drug Administration (FDA) has approved a once-monthly dosing schedule for amivantamab, a treatment for non-small cell lung cancer (NSCLC) whose tumors have specific EGFR mutations. The approval expands the administration options for the bispecific antibody, initially approved in December for biweekly subcutaneous injection.

The new monthly schedule, delivered via subcutaneous injection with hyaluronidase-lpuj (marketed as Rybrevant Faspro), maintains the drug’s efficacy and safety profile established in prior trials, according to the FDA. This change is expected to reduce the frequency of clinic visits and potentially decrease infusion-related reactions for patients.

Amivantamab is designed to target and block the EGFR receptor, a protein often overexpressed in NSCLC, hindering cancer cell growth. The approval applies to all previously authorized indications for the drug, meaning patients with locally advanced or metastatic NSCLC harboring EGFR mutations are now eligible for the less frequent dosing regimen.

Clinical trials demonstrated that the monthly dosing schedule yielded comparable results to the biweekly injections, providing a more convenient option for patients undergoing treatment. The change aims to improve patient quality of life by minimizing the disruption caused by frequent medical appointments.

The FDA’s decision follows positive data indicating that the monthly administration does not compromise the drug’s effectiveness in controlling tumor growth or managing side effects. The approval is expected to streamline treatment protocols and enhance accessibility for individuals with this specific type of lung cancer.

The subcutaneous formulation of amivantamab, Rybrevant Faspro, was initially approved to provide a less invasive alternative to intravenous infusions. The addition of a monthly dosing option further builds on this approach, offering increased flexibility for both patients and healthcare providers.